Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
About the Company : Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in mark...
About the Company : Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer. We have a legacy of over three decades and trace our origins to the API e...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on guideline-recommended renin-angiotensin-aldosterone system inhibitor therapy.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Brand Name: Veltassa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Lead Product(s) : Patiromer
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
DIAMOND trial: Veltassa® Enables Patients to Achieve Long-term Potassium Control and Optimized RA...
Details : Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on guideline-recommended renin-angiotensin-aldosterone system inhibitor therapy.
Product Name : Veltassa
Product Type : Small molecule
Upfront Cash : Not Applicable
April 04, 2022
Details:
Veltassa (patiromer), Phase-IIIb diamond trial demonstrates statistically significant outcome on the primary endpoint and, enabled 85% of patients to be optimized to guideline-recommended doses of RAASi.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Brand Name: Veltassa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Lead Product(s) : Patiromer
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vifor Pharma Reports Positive Outcome of The Phase-IIIb DIAMOND Trial of Veltassa
Details : Veltassa (patiromer), Phase-IIIb diamond trial demonstrates statistically significant outcome on the primary endpoint and, enabled 85% of patients to be optimized to guideline-recommended doses of RAASi.
Product Name : Veltassa
Product Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2021
Details:
Vifor Pharma continues to drive evidence-based care using Veltassa® through multiple additional trial activities. phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Brand Name: Veltassa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Lead Product(s) : Patiromer
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vifor Pharma to revise DIAMOND Study, readout expected in H2 2021
Details : Vifor Pharma continues to drive evidence-based care using Veltassa® through multiple additional trial activities. phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints.
Product Name : Veltassa
Product Type : Small molecule
Upfront Cash : Not Applicable
June 24, 2021
Details:
CARE-HK in HF is designed to evaluate the use of Veltassa® in enabling patients to remain on RAASi therapy in HF patients with or at high risk for HK.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Brand Name: Veltassa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
Lead Product(s) : Patiromer
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
First Patient Enrolled in CARE-HK in HF to Evaluate Role of Veltassa® (Patiromer) in Enabling RAA...
Details : CARE-HK in HF is designed to evaluate the use of Veltassa® in enabling patients to remain on RAASi therapy in HF patients with or at high risk for HK.
Product Name : Veltassa
Product Type : Small molecule
Upfront Cash : Not Applicable
April 28, 2021
Details:
Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.
Lead Product(s): Patiromer
Therapeutic Area: Nephrology Brand Name: Veltassa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Fresenius Kabi AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 19, 2020
Lead Product(s) : Patiromer
Therapeutic Area : Nephrology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Fresenius Kabi AG
Deal Size : Undisclosed
Deal Type : Collaboration
VFMCRP and Fresenius Kabi Expand Collaboration in Nephrology in China with Veltassa® Agreement
Details : Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chroni...
Product Name : Veltassa
Product Type : Small molecule
Upfront Cash : Undisclosed
November 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
Company :
Patiromer Calcium Sorbitex
Drug Cost (USD) : 110,617,058
Year : 2022
Prescribers : 29512
Prescriptions : 105685
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Patiromer Calcium Sorbitex
Drug Cost (USD) : 105,568,566
Year : 2021
Prescribers : 28431
Prescriptions : 104585
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Patiromer Calcium Sorbitex
Drug Cost (USD) : 111,516,027
Year : 2020
Prescribers : 29988
Prescriptions : 116485
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
Comment (2)
